Search Results
Your search for ,foR matches 32393 pages
Showing 21101 - 21150Palliative Care Still in Its Infancy in Hematologic Malignancies
Palliative care is slowly but surely being integrated into the treatment of patients with solid tumors, but its role in the hematopoietic stem cell transplant setting is still lagging, speakers said at the 2016 Palliative Care in Oncology Symposium. “There is a huge symptom burden among patients...
Donor Selection for HLA-Matched Hematopoietic Cell Transplantation
Question 1: Which statement about donor selection for allogeneic hematopoietic cell transplant is correct? Correct Answer: C. If a donor is available, the genotypic identity between the patient and his brother should be established by typing the patient’s parents; if this is not possible, the...
Donor Selection for HLA-Matched Hematopoietic Cell Transplantation
Case Study A 33-year-old white male is diagnosed with acute myeloid leukemia (AML) with complex cytogenetics. A decision is made in favor of performing allogeneic hematopoietic cell transplantation in first complete remission. The patient has a 35-year-old brother who is healthy and motivated to...
Bromelain
Scientific Names: Sulfydryl proteolytic enzyme, cysteine proteinase Common Names: Ananase, Dayto Anase, Traumanase Overview Derived from the fruits and stems of pineapples, bromelain is a proteolytic enzyme that is used to treat burns and skin conditions, and as an anti-inflammatory agent....
New NCCN Patient Resources Assist Decision-Making for Patients With Stomach Cancer
According to the American Cancer Society, it is estimated that more than 26,000 people will be diagnosed with stomach cancer in the United States this year, with nearly 1 million new cases diagnosed worldwide each year, according to the World Health Organization. Because there are no early symptoms ...
Using Pharmacogenetics to Predict Cancer Prognosis, Response to Treatment, and Toxicity
Although clinical trials are helpful in determining the effectiveness of a specific drug across a patient population, they are not as reliable at pinpointing how well a particular patient will respond to the drug or dosing regimen or how the drug may impact the patient’s quality of life from...
ESMO 2016: Longer Interval Between Preoperative Chemoradiotherapy and Surgery Urged in Locally Advanced Rectal Cancer
A longer waiting interval from the end of preoperative chemoradiotherapy to surgery increases the rate of pathologic complete response and yields a higher proportion of patients achieving tumor downstaging in patients with locally advanced rectal cancer, according to new findings from a...
Sanford Research in South Dakota Receives NIH Grant in Head and Neck, Pediatric Cancers
The Cancer Biology Research Center at Sanford Research in Sioux Falls, South Dakota, is the recipient of a 5-year, nearly $11.7 million grant from the National Institutes of Health (NIH) to translate laboratory research into clinical trials for head and neck and pediatric cancers. The grant was...
Rise in Oropharyngeal Cancer Incidence in the UK Not Solely Driven by HPV
The rise in the incidence of oropharyngeal squamous cell carcinoma in the United Kingdom from 2002 to 2011 was not solely attributable to a rise in the incidence of human papillomavirus (HPV)-positive disease, according to a study published in Cancer Research,1 which reported that the proportion of ...
ESMO 2016: Dabrafenib/Trametinib/Panitumumab Improves Efficacy in BRAF Mutation–Positive Metastatic Colorectal Cancer
Patients with metastatic colorectal cancer and tumors harboring the BRAF V600E mutation who received triple therapy with dabrafenib (Tafinlar), trametinib (Mekinist), and panitumumab (Vectibix) showed an improved best overall response and prolonged progression-free survival compared to...
Barriers and Opportunities Reported in the Study of Human Papillomavirus Education and Immunization Efforts
Human papillomavirus (HPV) vaccination rates remain low across the United States, with fewer than 40% of girls and just over 21% of boys receiving the recommended vaccine series. Research from Roswell Park Cancer Institute has identified barriers that need to be overcome to improve vaccination...
ESMO 2016: Vemurafenib Shows Clinical Benefit in Diverse BRAF V600–Mutated Tumors
Findings from a phase II trial of vemurafenib in previously treated patients with advanced disease and BRAF-mutated tumors indicate that the drug is effective in patients with diverse BRAF V600–mutated tumors but not in patients with BRAF non-V600 mutations. After a mean treatment...
Expert Point of View: Elizabeth Jaffee, MD
Elizabeth Jaffee, MD, Deputy Director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, commented on the promise of neoantigens during a press briefing at the 2nd International Cancer Immunotherapy Conference. “In addition to the development of new drugs...
Personalized Vaccines May Protect Patients With High-Risk Melanoma
The field of cancer vaccines may be reinvigorated by a new understanding, and the therapeutic leveraging, of neoantigens. Researchers from Dana-Farber Cancer Institute in Boston are exploring this novel approach as a means of protecting patients with high-risk melanoma from recurrence. Early...
When Breath Becomes Air: Dr. Lucy Kalanithi Reflects on Dr. Paul Kalanithi’s Life and Writing
Perhaps more than any other book in recent memory, When Breath Becomes Air has struck a chord among readers, both inside the medical community and among the public, desiring an honest and philosophical consideration of death. The autobiographical account of Paul Kalanithi, MD, a physician diagnosed ...
Association of PD-L1 Expression and Response to Pembrolizumab in Advanced Melanoma
In an analysis from the phase IB KEYNOTE-001 trial, Daud et al found that the level of programmed cell death ligand 1 (PD-L1) expression was associated with outcomes of pembrolizumab (Keytruda) treatment in patients with advanced melanoma. These findings were reported in the Journal of Clinical...
Study Finds Nivolumab Improves Survival vs Standard Therapy in Recurrent Squamous Cell Carcinoma of the Head and Neck
In the phase III CheckMate 141 trial reported in The New England Journal of Medicine, Ferris et al found that nivolumab (Opdivo) increased overall survival vs standard therapies in patients with recurrent platinum-refractory squamous cell carcinoma of the head and neck. Study Details In this...
ASCO Answers Palliative Care: A Resource for Patients
ASCO Answers Palliative Care is an informative booklet that shows how palliative care is used to manage symptoms and side effects; help with practical concerns; address spiritual questions; and support family, friends, and caregivers at any stage of cancer. It also gives practical advice about...
Leave a Legacy of Hope
By including a planned gift to the Conquer Cancer Foundation in your estate plans, you can help make a dramatic difference for cancer patients years—even decades—into the future. With just one small change to your will or trust, your planned gift of any size will deliver a big impact, and: Your...
Arti Hurria, MD: From Leadership Development Program to Board of Directors
Arti Hurria, MD, a geriatric oncologist at City of Hope in Duarte, California, is the first graduate of ASCO’s Leadership Development Program to be elected to ASCO’s Board of Directors. Within 5 years of completing the program, Dr. Hurria went from learning leadership skills to applying them to...
New Member Categories Provide Specialized Support to Cancer Care Team Members
As part of ASCO’s ongoing effort to fully support all members of the cancer care team, it recently created three new member categories: Advanced Practice Providers, Practice Administrators, and Patient Advocates (see sidebar). Originally part of the Affiliated Health Professionals member category, ...
ASCO Presents First-Ever ASCO Congressional Leadership Award to Representative Michael Burgess, MD
ASCO presented Representative Michael Burgess, MD (TX-26) with the Society’s first-ever ASCO Congressional Leadership Award to recognize his steadfast work to advance policies that support cancer research and treatment. This new, annual award honors a Member of Congress who is a dedicated champion ...
Free PQRS Reporting Now Available Through QOPI®; No Additional Reporting Required
ASCO is pleased to announce that oncology practices can now complete all of their Physician Quality Reporting System (PQRS)1 requirements through the Quality Oncology Practice Initiative (QOPI®) platform. All users will be able to use the QOPI system to fulfill the Oncology Measures Group set of 7...
Precision Promise Clinical Trial Focuses on Precision Medicine, Collaboration, and Data-Sharing in Pancreatic Cancer
The Pancreatic Cancer Action Network recently announced Precision Promise, the first large-scale precision medicine trial designed to transform outcomes for patients with pancreatic cancer. The organization also announced the 12 initial Precision Promise Clinical Trial Consortium sites selected to...
St. Jude Children’s Research Hospital and Sanger Institute, UK Agree to Full Exchange of Cancer Data
St. Jude Children’s Research Hospital and the Wellcome Trust Sanger Institute, UK, have agreed to a full exchange of cancer mutation data to support the discovery and understanding of genetic mutations causing cancers. The agreement will provide regular updates and exchanges of data between both...
What We Know and What We Need to Know About Neoadjuvant Chemotherapy in Advanced Ovarian Cancer
Ever since the landmark studies of Griffiths and colleagues in the 1970s,1 primary cytoreductive surgery followed by chemotherapy with the objective of achieving minimal residual disease has been the standard approach for women with advanced-stage epithelial ovarian cancer. However, what is...
SGO and ASCO Clinical Practice Guideline on Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer
As reported by Alexi A. Wright, MD, MPH, of Dana-Farber Cancer Institute, and colleagues in the Journal of Clinical Oncology, ASCO and the Society of Gynecologic Oncology (SGO) have released a clinical practice guideline on neoadjuvant therapy for patients with newly diagnosed stage IIIC or IV...
Expert Point of View: Olivier Michielin, MS, MD, PhD
The paper’s invited discussant was Olivier Michielin, MS, MD, PhD, Head of Personalized Analytical Oncology and the Melanoma Clinic at Lausanne University Hospital in Switzerland. He called the findings of the European Organisation for Research and Treatment (EORTC) 18071 trial a “new landmark in...
Adjuvant Ipilimumab Improves Survival in High-Risk Melanoma
Patients with stage III melanoma who were considered to be at high risk for recurrence derived an overall survival benefit from adjuvant treatment with ipilimumab (Yervoy), although it came at the price of considerable toxicity, according to updated survival results from the phase III European...
Quality Science at ESMO 2016
Andrés Cervantes, MD, PhD, Scientific Chair of the 2016 European Society for Medical Oncology (ESMO) Congress, concluded the meeting earlier this month by recognizing a number of important take-home messages. At a closing press conference, Dr. Cervantes noted that the “ESMO 2016 Congress has...
Mount Sinai and Thomas Jefferson University Researchers Receive Falk Foundation Grant to Study Uveal Melanoma
Uveal melanoma is the second most common type of skin cancer. Approximately 50% of patients with uveal melanoma will develop metastasis, most commonly to the liver. The disease can appear more than 10 years after the primary lesion has been removed, lying dormant for long periods. There are...
UPMC Honors Stanley M. Marks, MD, With Endowed Chair in Hematology/Oncology Leadership
The University of Pittsburgh Medical Center (UPMC) announced that Stanley M. Marks, MD, oncologist and advocate for cancer patients throughout the western Pennsylvania region, is being honored by the UPMC and his medical partners at Oncology Hematology Association (OHA) through the establishment...
Huntsman Cancer Institute Names Ben Tanner Executive Director
University of Utah Health Care (UUHC) has named Ben Tanner, Huntsman Cancer Institute’s current Director of Clinical Operations and Chief Operating Officer (COO), as the Institute’s Executive Director, replacing Ray Lynch, who is retiring after 13 years of service. Mr. Tanner has been COO of the...
With Changing Strategies for Laryngeal Cancer, Multidisciplinary Team Approach Is Key
The treatment of cancer of the larynx has changed dramatically in recent years. With organ preservation now possible in many cases, it is more important than ever for patients to receive guidance from every corner of the field. In a recent article in the Journal of Oncology Practice (JOP),1 a...
NIH Expands National Precision Medicine Initiative Cohort Program
The National Institutes of Health (NIH) has announced awards to add four regional medical center groups to the national network of health-care provider organizations that will implement the Precision Medicine Initiative Cohort Program. Combined, the new health-care provider organizations will...
German Society Salutes ‘Big Four’ for Pioneering Work in Women’s Health Care
Diethelm Wallwiener, MD, President of the German Society for Gynaecology and Obstetrics, announced “The Big Four of the Millennium” at the 61st Congress of the Society, held recently in Stuttgart, Germany. The award recognizes individuals’ whose work in the 20th century created the standards of...
Consensus on Defining and Measuring Lymphedema Is Needed to Advance Efforts to Intervene Early and Prevent Progression
“Early intervention might prevent lymphedema progression,” Alphonse Taghian, MD, PhD, said at the 18th Annual Lynn Sage Breast Cancer Symposium in Chicago, but the lack of a universal definition of lymphedema and agreement on how to optimally measure it impedes phase III studies to test that...
Mammography-Detected Small Breast Cancers May Represent Overdiagnosis, With Survival Gains Reflecting Improved Systemic Therapy
In a study using SEER (Surveillance, Epidemiology, and End Results) data reported in The New England Journal of Medicine, Welch et al found that screening mammography has resulted in a substantial increase in detection of small breast tumors, many of which represent overdiagnosis, accompanied by...
Study Finds Adjuvant Sunitinib Improves Disease-Free Survival in High-Risk Renal Cell Carcinoma After Nephrectomy
In the phase III S-TRAC trial reported at the 2016 European Society for Medical Oncology Congress and in The New England Journal of Medicine by Ravaud et al, adjuvant sunitinib (Sutent) significantly prolonged disease-free survival vs placebo in patients with high-risk renal cell carcinoma after...
Breast Cancer Study Finds Higher Mortality Rate in Black Women Than White Women, and the Disparity Is Growing
The Avon Foundation for Women recently released a new study on the racial disparities in breast cancer mortality in the 50 largest cities in the United States between 2005 and 2014. Published in Cancer Epidemiology,1 the study was conducted by Sinai Urban Health Institute in collaboration with the...
FDA Grants Accelerated Approval to Olaratumab for Treatment of Advanced Soft-Tissue Sarcoma
Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to olaratumab (Lartruvo) in combination with doxorubicin to treat adults with certain types of soft-tissue sarcoma. Olaratumab is approved for use with the FDA-approved chemotherapy drug doxorubicin for the treatment of ...
NCCN Issues New Clinical Practice Guidelines for Myeloproliferative Neoplasms
Myeloproliferative neoplasms are a group of blood cancers characterized by significant symptoms and a high risk of transformation into acute leukemia. These cancers—myelofibrosis, essential thrombocythemia, and polycythemia vera—affect approximately 13,000; 134,000; and 148,000 patients in the...
Expert Point of View: Colleen A. Lawton, MD
“This is very exciting work and is exactly what we need in prostate cancer,” said Colleen A. Lawton, MD, Vice-Chair of the Medical College of Wisconsin, Milwaukee, and moderator of a press conference where the study by Spratt et al was discussed. “The prognostic measures we use are rough and...
Prognostic and Predictive Molecular Subtypes of Prostate Cancer Identified
Members of the oncology community have long complained that prostate cancer lags behind breast cancer regarding biomarkers for prognosis and treatment, but the good news is that this gap is narrowing. In the largest study of its kind to date, presented at the 58th Annual Meeting of the American...
Nancy E. Davidson, MD, to Lead Fred Hutchinson/University of Washington Cancer Consortium
Fred Hutchinson Cancer Research Center announced that Nancy E. Davidson, MD, Director of the University of Pittsburgh Cancer Institute, has accepted the position of Executive Director of the Fred Hutchinson/University of Washington Cancer Consortium—1 of the 47 National Cancer Institute–designated ...
ESMO 2016: Pooled Analysis Shows PD-L1 Expression as a Biomarker for Nivolumab Plus Ipilimumab Response in Advanced Melanoma
A pooled analysis from three clinical trials in advanced melanoma shows that although patients treated with nivolumab and nivolumab plus ipilimumab with ≥ 5% programmed death-ligand 1 (PD-L1) tumor expression have similar progression-free survival, durable response rates were higher for the...
ESMO 2016: Meta-analysis Confirms Superiority of Concomitant Over Induction Chemotherapy in Nonmetastatic Head and Neck Cancer
Patients with head and neck squamous cell carcinoma achieved prolonged overall survival when concomitant chemotherapy was administered with locoregional treatment or radiotherapy, according to findings from a large meta-analysis reported by Blanchard et al at the European Society for Medical...
Expert Point of View: Vinai Gondi, MD
Formal discussant of both trials, Vinai Gondi, MD, Director of CNS Radiation Oncology at Northwestern Medicine Cancer Center in Warrenville, Illinois, offered a somewhat more nuanced take on the data from these studies. To begin, he commended the authors of both studies. “These were both...
ESMO 2016: Clinical Benefit Demonstrated With Everolimus and Pasireotide LAR Alone or in Combination in Advanced Lung and Thymic Carcinoids
In patients with advanced lung or thymus carcinoid receiving everolimus, pasireotide LAR, or the combination of the two drugs, statistically significant positive impact was seen on proportion of patients’ progression-free rate at 9 months (primary endpoint) in all three arms, more relevant in ...
Stereotactic Radiosurgery Achieves Better Quality of Life and Improved Cognition Than Whole-Brain Radiotherapy
Two separate randomized trials presented at the 58th Annual Meeting of the American Society of Radiation Oncology (ASTRO) affirmed the value of stereotactic radiosurgery as an option for postoperative treatment of the surgical cavity of resected brain metastases, potentially avoiding the cognitive...
